# Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure

Study · id `cardio:ct-nct07023016` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07023016](<https://clinicaltrials.gov/study/NCT07023016>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07023016

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 515 participants.

## Technical summary

Registry record NCT07023016. Randomized; no masking; primary purpose treatment. Start 2023-11-01 (actual); primary completion 2025-02-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 515 participants (enrolled count; ClinicalTrials.gov record NCT07023016, source copy `cardio:ctgov-nct07023016-2026-08-13`, retrieved 2026-10-26)
- Started: 2023-11-01 (actual) (ClinicalTrials.gov record NCT07023016, source copy `cardio:ctgov-nct07023016-2026-08-13`, retrieved 2026-10-26)
- Primary completion: 2025-02-28 (actual) (ClinicalTrials.gov record NCT07023016, source copy `cardio:ctgov-nct07023016-2026-08-13`, retrieved 2026-10-26)
- Completion: 2025-02-28 (actual) (ClinicalTrials.gov record NCT07023016, source copy `cardio:ctgov-nct07023016-2026-08-13`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT07023016, source copy `cardio:ctgov-nct07023016-2026-08-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07023016-2026-08-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure
- Acronym: CAESAR
- Condition: Acute Decompensated Heart Failure (ADHF)
- Condition: Chronic Kidney Disease (CKD)
- Intervention (Drug): Sacubitril / Valsartan
- Intervention (Drug): Ramipril (ACE-inhibitor)
- Lead sponsor: National Heart Institute, Egypt
- Lead sponsor class: OTHER\_GOV
- Collaborator: Cairo University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: National Heart Institute, Egypt (`cardio:org-national-heart-institute-egypt`)
- Registry lists this organization as a collaborator: Cairo University (`cardio:org-cairo-university`)

## Provenance

Content hash: 4ac578c089b0cda9d4370094ea2614926e370f200fc9212ee070154e3f7f3f4e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
